(Q54606278)

1 June 2018

title

VEGF-D correlates with metastatic disease in gastric cancer patients undergoing surgery. (English)

1 reference

1 June 2018

author

George Sgourakis

5

1 reference

1 June 2018

author name string

Carl C Schimanski

1

1 reference

1 June 2018

Friederike Schlaegel

2

1 reference

1 June 2018

Mareike Jordan

3

1 reference

1 June 2018

Markus Moehler

4

1 reference

1 June 2018

Daniel G Drescher

6

1 reference

1 June 2018

Peter R Galle

7

1 reference

1 June 2018

Hauke Lang

8

1 reference

1 June 2018

Ines Gockel

9

1 reference

1 June 2018

publication date

1 May 2011

1 reference

1 June 2018

published in

World Journal of Surgery

1 reference

1 June 2018

volume

35

1 reference

1 June 2018

issue

5

1 reference

1 June 2018

page(s)

1010-1016

1 reference

1 June 2018

Global cancer statistics, 2002

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Gastric cancer: who is at risk?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Gastric cancer: a curable disease in Britain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Early gastric cancer: lymph node metastasis starts with deep mucosal infiltration

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Patient survival after D1 and D2 resections for gastric cancer: long-term results of the MRC randomized surgical trial. Surgical Co-operative Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

The multidisciplinary management of gastrointestinal cancer. Multimodal treatment of gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Coexpression of receptor-tyrosine-kinases in gastric adenocarcinoma--a rationale for a molecular targeting strategy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Genes critical to vasculogenesis as defined by systematic analysis of vascular defects in knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Targeted agents for the treatment of advanced renal cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

VEGF-D expression correlates with colorectal cancer aggressiveness and is downregulated by cetuximab

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Capecitabine and oxaliplatin for advanced esophagogastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Correlation of vascular endothelial growth factor-D expression and VEGFR-3-positive vessel density with lymph node metastasis in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Vascular endothelial growth factor-D and its receptor VEGFR-3: two novel independent prognostic markers in gastric adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Prognostic significance of vascular endothelial growth factor D in gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Expression of vascular endothelial growth factor (VEGF)-C and VEGF-D in early gastric carcinoma: correlation with clinicopathological parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00268-011-1041-7

Extended lymph-node dissection for gastric cancer

21 January 2018

1 reference

12 December 2020

Does expression of receptor tyrosine kinases in gastric adenocarcinoma correlate with clinicopathological parameters?

1 reference

12 December 2020

Distinct roles of VEGF-A and VEGF-C in tumour metastasis of gastric carcinoma

1 reference

12 December 2020

Cetuximab with irinotecan, folinic acid and 5-fluorouracil as first-line treatment in advanced gastroesophageal cancer: a prospective multi-center biomarker-oriented phase II study.

1 reference

12 December 2020

Platelet- derived growth factor--the construction, role and it's receptors

1 reference

12 December 2020

A new prognostic strategy for gastric carcinoma: mRNA expression of tumor growth-related factors in endoscopic biopsy specimens

1 reference

12 December 2020

Prognostic value of platelet-derived growth factor-A (PDGF-A) in gastric carcinoma

1 reference

12 December 2020

Principles of surgical treatment for curable gastric cancer

1 reference

12 December 2020

Prognostic relevance of systematic lymph node dissection in gastric carcinoma. German Gastric Carcinoma Study Group

1 reference

12 December 2020

Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial

1 reference

12 December 2020

Histopathological predictor for regional lymph node metastasis in gastric cancer

1 reference

12 December 2020

VEGF-C and VEGF-A synergistically enhance lymph node metastasis of gastric cancer

1 reference

12 December 2020

Extended versus limited lymph nodes dissection technique for adenocarcinoma of the stomach

1 reference

12 December 2020

Phase II study of sunitinib as second-line treatment for advanced gastric cancer

1 reference

12 December 2020

Vascular endothelial growth factor C (VEGF-C) expression in pT2 gastric cancer

1 reference

12 December 2020

10.1007/S00268-011-1041-7

Identifiers

DOI

1 reference

1 June 2018

1 reference

1 June 2018